What it is
Tirzepatide is a dual incretin medicine that acts on GLP-1 and GIP pathways. It is a prescription peptide medicine with large published trials in type 2 diabetes and obesity. Brand names people may have seen include Mounjaro and Zepbound. We do not prescribe it or sell it.
Studied for
- Type 2 diabetes, in large published randomized trials.
- Obesity, in large published randomized trials.
- Gut–brain signaling through GLP-1 and GIP pathways.
The evidence
Human trial. In this library it sits with semaglutide: large, published randomized trials, not animal-only research and not an anecdote. We are not ranking it against semaglutide. Both have a formal human-trial record, and a prescriber is who compares them for a real person.
What this page will not do
- A published trial is not a suggestion that you should take it.
- We do not give doses or switching schedules.
- Approved uses are specific. Confirm the current label.
Still open
- Which incretin medicine, if any, belongs in a particular care plan.
- How trade-offs described in the trials apply outside a study population.
Educational content only. This page does not diagnose, treat, cure, or prevent anything, and it is not a dose. Talk with a licensed physician before starting, stopping, or changing any medication. Library reviewed November 2026.